Publication of List of Manufacturers Suspended From Licensing for the Manufacture of Therapeutic Goods – 31 May 2023

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was introduced to regulate the quality, safety, and efficacy of therapeutic goods in Australia, including medicines, medical devices, and blood products. This legislation aims to protect public health by ensuring that therapeutic goods available in Australia meet necessary standards and are safe for use. The Act empowers the Therapeutic Goods Administration (TGA) to oversee the licensing of therapeutic goods and to enforce measures such as the suspension of manufacturing licenses when necessary to safeguard public health. The TGA, a branch of the Department of Health and Aged Care, administers this Act and its policy objective is to ensure that therapeutic goods available in Australia are of acceptable quality, are safe for use, and perform as claimed.

Scope and Application

The Therapeutic Goods Act 1989 applies to a range of entities including individuals, companies, and other legal persons involved in the manufacture, supply, or distribution of therapeutic goods within Australia. The scope of the Act encompasses the entire lifecycle of therapeutic goods, from initial research and development through to manufacture, importation, supply, and advertising. This legislation applies to entities operating across various sectors such as pharmaceuticals, medical devices, blood, and tissues. The Act’s jurisdictional reach is national, applying throughout the Commonwealth of Australia, and it extends to entities regardless of where the therapeutic goods are manufactured, supplied, or intended for use within Australia. The Act’s provisions can be extended or modified through subordinate instruments, which may include regulations and guidelines issued by the Therapeutic Goods Administration (TGA). In certain cases, the Act provides for exclusions and exemptions, often based on the type and intended use of the therapeutic goods, but these are narrowly defined and subject to specific conditions. The publication of a list of manufacturers suspended from licensing, such as the recent suspension of Global Medical Solutions Australia Pty Limited, underscores the TGA’s commitment to ensuring the safety and quality of therapeutic goods available in the Australian market.

Key Provisions

The Therapeutic Goods Administration (TGA) has published a notice under Section 41(1)(d) of the Therapeutic Goods Act 1989, indicating the suspension of a Licence to Manufacture Therapeutic Goods. Specifically, Global Medical Solutions Australia Pty Limited, with Licence number MI-26112004-LI-000234-1, located at 12/81 Bishop Street, Kelvin Grove, QLD, 4059, has had its licence suspended. This suspension was requested by the manufacturer and is effective from 9 March 2023 until 10 March 2024. The main operative section referenced here is Section 41(1)(d) of the Therapeutic Goods Act 1989, which provides the authority for the Secretary to suspend a licence. This suspension is intended to protect public health and safety by ensuring that the quality and safety of therapeutic goods meet regulatory standards. The notice specifies the name of the manufacturer, the licence number, and the address where the manufacturing activities are conducted, along with the period during which the licence is suspended. The obligations and requirements imposed by this Act on the manufacturer, Global Medical Solutions Australia Pty Limited, include adherence to stringent quality control measures, regular reporting to the TGA, and compliance with any other relevant regulations pertaining to the manufacture of therapeutic goods. Failure to meet these obligations can result in the suspension of their licence, as evidenced by this notice. Additionally, the manufacturer must ensure that their operations do not compromise the safety, efficacy, or quality of the therapeutic goods they produce. Under the Therapeutic Goods Act 1989, breaches of the Act can result in both civil and criminal consequences. For example, knowingly supplying therapeutic goods that do not comply with the Act can result in significant penalties. Civil penalties can include fines up to a specified maximum amount, while criminal penalties may include imprisonment. The specific maximum penalties are detailed in other sections of the Act and can vary based on the severity of the breach. The suspension of a licence itself is a strong regulatory action that can lead to further enforcement measures if the underlying issues are not rectified within the stipulated period.